Discontinued — last reported Q4 '23
Products & Services · Deferred revenues
Paxlovid — Deferred revenues
Analysis
StatementSegment
First reportedQ4 2021
Last reportedQ4 2023Feb 22, 2024
Rolls up toContract Liabilities
Metric ID:
pfe_segment_paxlovid_deferred_revenuesHistorical Data
2 periods
| Q4 '21 | Q4 '23 | |
|---|---|---|
| Value | $0 | $1.5B |
Range$0 – $1.5B
Frequently Asked Questions
- What is Pfizer's paxlovid — deferred revenues?
- Pfizer (PFE) reported paxlovid — deferred revenues of $1.5B in Q4 2023.